Atara Non Current Assets Total from 2010 to 2024
ATRA Stock | USD 0.71 0.01 1.39% |
Non Current Assets Total | First Reported 2013-12-31 | Previous Quarter 74.1 M | Current Value 70.1 M | Quarterly Volatility 34.7 M |
Check Atara Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atara main balance sheet or income statement drivers, such as Interest Expense of 3.8 M, Selling General Administrative of 51.5 M or Other Operating Expenses of 202.9 M, as well as many exotic indicators such as Price To Sales Ratio of 5.75, Dividend Yield of 0.0032 or Operating Cycle of 256. Atara financial statements analysis is a perfect complement when working with Atara Biotherapeutics Valuation or Volatility modules.
Atara | Non Current Assets Total |
Latest Atara Biotherapeutics' Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Atara Biotherapeutics over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Atara Biotherapeutics' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atara Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
Timeline |
Atara Non Current Assets Total Regression Statistics
Arithmetic Mean | 40,756,003 | |
Geometric Mean | 3,624,656 | |
Coefficient Of Variation | 99.90 | |
Mean Deviation | 37,505,736 | |
Median | 45,589,000 | |
Standard Deviation | 40,714,551 | |
Sample Variance | 1657.7T | |
Range | 98.2M | |
R-Value | 0.94 | |
Mean Square Error | 217.3T | |
R-Squared | 0.88 | |
Slope | 8,531,923 | |
Total Sum of Squares | 23207.4T |
Atara Non Current Assets Total History
About Atara Biotherapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Atara Biotherapeutics income statement, its balance sheet, and the statement of cash flows. Atara Biotherapeutics investors use historical funamental indicators, such as Atara Biotherapeutics's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Atara Biotherapeutics investors may use each financial statement separately, they are all related. The changes in Atara Biotherapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atara Biotherapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Atara Biotherapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Atara Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for 2024 | ||
Non Current Assets Total | 93.5 M | 98.2 M |
Pair Trading with Atara Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atara Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atara Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Atara Stock
0.6 | CALT | Calliditas Therapeutics Financial Report 21st of May 2024 | PairCorr |
0.57 | PFE | Pfizer Inc Fiscal Quarter End 31st of March 2024 | PairCorr |
0.52 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
0.52 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
0.49 | CVS | CVS Health Corp Financial Report 1st of May 2024 | PairCorr |
The ability to find closely correlated positions to Atara Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atara Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atara Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atara Biotherapeutics to buy it.
The correlation of Atara Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atara Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atara Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atara Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Atara Biotherapeutics Correlation against competitors. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Atara Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.78) | Revenue Per Share 0.043 | Quarterly Revenue Growth (0.52) | Return On Assets (0.64) | Return On Equity (4.26) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.